Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Trial of Neoadjuvant and Adjuvant Atezolizumab With or Without Tiragolumab in Conjunction With Chemoradiotherapy for Unresectable Stage III NSCLC

NCT05798663 is registered in ClinicalTrials.gov with Alliance Foundation Trials, LLC. as lead sponsor.

NCT NCT05798663
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05798663 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Trial of Neoadjuvant and Adjuvant Atezolizumab With or Without Tiragolumab in Conjunction With Chemoradiotherapy for Unresectable Stage III NSCLC
Lead sponsor
Alliance Foundation Trials, LLC.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 7, 2023
Completion date
February 28, 2027
Enrollment
178 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc